Foundayo is orforglipron, from Eli Lilly, approved on April 1, 2026 for weight management. It is the second GLP-1 tablet licensed for that purpose, after the Wegovy tablet. Unlike oral semaglutide, it is not a peptide, which is why it comes with no fasting window and no elaborate instructions about water.
You take one tablet a day, swallowed whole, and never more than one in a day.
The ladder
| Dose | Hold at least | What it is |
|---|---|---|
| 0.8 mg | 30 days | A run-up rather than a treatment dose. Its purpose is your stomach, not your weight. |
| 2.5 mg | 30 days | The first step that is doing something. Stay longer if the nausea has not settled. |
| 5.5 mg | 30 days | Middle of the ladder. |
| 9 mg | 30 days | A perfectly reasonable place to stop if the rungs above disagree with you. |
| 14.5 mg | 30 days | Second from top. Staying here is allowed if it works and you tolerate it. |
| 17.2 mg | — | The maximum, and the dose that produced the headline trial result. |
Each step is held a minimum of thirty days, and whether you climb past the middle depends on how you are responding and what you can tolerate. The 17.2 mg dose is the maximum, and you do not have to reach it.
Taking it
- Food is irrelevant. No empty stomach, no measured sip of water, no waiting before breakfast. This is the clearest practical difference from oral semaglutide. The reason is chemistry: a non-peptide does not need shielding from your digestion.
- Same time each day, whichever time fits your life.
- Swallow it whole. Do not split, crush or chew it.
- One a day, maximum, no matter what happened yesterday.
- No fridge, no needles.
Interactions: the part that is easy to skip
This is where a tablet is more complicated than an injection. Orforglipron is processed by CYP3A4, so other medicines change its levels and it changes theirs. Injectable GLP-1s are peptides and largely avoid this territory altogether.
- Strong CYP3A4 inhibitors: your maximum drops to 9 mg a day. If the drug also blocks OATP1B, do not combine them at all.
- Strong CYP3A4 inducers: avoid. With moderate ones, expect Foundayo to work less well and the dose to need review.
- Simvastatin: held to 20 mg daily alongside it.
- Oral contraceptives: the label tells users to switch to a method that is not swallowed or to add a barrier method. That advice covers the first 30 days on the drug and the 30 days after every dose increase. It matters because the drug can harm a developing pregnancy and should stop as soon as one is known about.
- Other tablets generally: gastric emptying slows, which can change how they are absorbed.
A missed tablet
The label's rule is short, because the schedule is daily.
- Missed one? Take it as soon as you can, then carry on as usual.
- Never double up the next dose. It buys nothing and costs you a day of nausea.
- Missed seven or more days running? Then the climb starts again from a lower dose, per the label, so talk to your prescriber before you resume.
The weekly injections use different windows of four or five days, so do not carry a habit from one to the other.
Reasons to pause and call
- Severe abdominal pain reaching through to the back. This can be pancreatitis. Stop and get assessed.
- Pain under the right ribs, fever, or yellowing. Gallbladder disease is a known class effect.
- Dehydration after prolonged vomiting or diarrhea. Kidney injury has followed this across the class. Hold the next dose, rehydrate and call someone.
- A new neck lump, hoarseness, difficulty swallowing. The boxed warning covers thyroid C-cell tumors. Anyone with medullary thyroid carcinoma in their history or their family's, or with MEN 2, cannot take this drug at all.
- Symptomatic low blood sugar, most likely alongside insulin or a sulfonylurea, which may need reducing.
- Rash, hives, swelling of the face or throat. Emergency care.
The most common complaints are gastrointestinal, and roughly one person in twenty stopped the drug in trials because of them.
Outside this page's scope
- How well it works. The short answer is 11.1% at the top dose over 72 weeks, which is below both injectable rivals. The longer answer, with the cross-trial caveats that go with it, is in our full write-up.
- Diabetes. This license covers weight management. Anything else is a separate question.
- Pregnancy, beyond the fact that this drug and pregnancy do not go together.
Where to go next
- Our full Foundayo write-up covers the trial numbers, the boxed-warning oddity and what four sellers we track charge for it.
- The Foundayo drug page has the label, indications and current pricing.
- The Medicare GLP-1 Bridge covers Foundayo, at a $50 monthly copay for those eligible.
- Brand names against molecules explains which pill is which, and why that decides your price.